Tue, Apr 15, 3:25 PM, Zacks
Eli Lilly/ Boehringer Drug Under FDA Review - Analyst Blog
Eli Lilly/ Boehringer new drug application (NDA) for their empagliflozin/Tradjenta (linagliptin) combination has been accepted for review by the FDA for type II diabetes.
Tue, Apr 15, 3:11 PM, Zacks
FDA Nod for Merck's Grastek - Analyst Blog
Merck announced that the FDA has approved Grastek, a timothy grass pollen allergen extract.